Acceleron commences ACE-536 phase 2 research in beta-thalassemia Acceleron Pharma, Inc., a biopharmaceutical company developing proteins therapeutics for tumor and orphan diseases, today announced the initiation of a phase 2 research of its novel, investigational proteins therapeutic, ACE-536, to take care of patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and significant problems affecting the spleen, liver and heart LevitraPrix.Net . Patients and healthcare suppliers have limited options for the treating beta-thalassemia currently. This is the second ongoing Phase 2 trial for ACE-536, which has been developed by Acceleron within a worldwide collaboration with Celgene Corporation .